Among them, the DYRK1A protein kinase is thought to be implicated in Alzheimer’s disease (AD) and Down syndrome, and as such, has emerged as an appealing therapeutic target. This evidence concerns the gene WEE1 and early-onset autosomal dominant Alzheimer disease.